Molecular Medicine Israel

ASCO GI: Immunotherapies Boosts Survival in Pancreatic Cancer

The combination of two anticancer vaccines demonstrated improved survival compared with a single vaccine in patients with advanced pancreatic cancer, a particularly difficult to treat tumor type with few therapy options. Patients treated with a combination of two vaccines, GVAX pancreas and CRS-207, had a median overall survival of 6.1 months compared with 3.9 months in patients treated with GVAX alone (hazard ratio [HR] = 0.59; P = .012). This is the first randomized study that has shown immunotherapy to be effective for advanced pancreatic cancer, according to the study presenter, Dung T. Le, MD, professor of medicine at the Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center in Baltimore, Maryland. The results of the randomized phase II trial were presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI)….

Sign up for our Newsletter